文献速递消化系统肿瘤

双周SLOG方案治疗转移性胰腺癌的I/II期多中心研究

A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
PubMed 文献 · Eur J Cancer · 2019-11-22

该I/II期研究评估S-1、亚叶酸钙、奥沙利铂和吉西他滨(SLOG)三药方案治疗初治转移性胰腺导管腺癌的可行性与疗效。I期确定S-1最大耐受剂量为35 mg/m2每日两次;II期54例患者客观缓解率40.7%,中位无进展生存7.6个月,中位总生存11.4个月,最常见III/IV级不良事件为中性粒细胞减少(40.7%)。

要点

  • 双周SLOG方案在转移性胰腺癌中可行,客观缓解率40.7%。
  • I期确定S-1最大耐受剂量为35 mg/m2每日两次。
  • 常见III/IV级不良事件为中性粒细胞减少(40.7%)。

核心结论

  • 双周SLOG方案可行,在转移性胰腺导管腺癌中显示出有前景的活性和安全性。

研究设计与样本

  • 多中心I/II期试验,纳入初治转移性胰腺导管腺癌患者,I期采用3+3设计确定S-1最大耐受剂量,II期主要终点为客观缓解率。

主要发现

  • I期确定S-1最大耐受剂量为35 mg/m2每日两次。
  • II期54例患者客观缓解率为40.7%(95%CI 28%-55%)。
  • 中位无进展生存期为7.6个月(95%CI 5.6-11.0),中位总生存期为11.4个月(95%CI 8.1-16.3)。
  • 吉西他滨、奥沙利铂和S-1的平均相对剂量强度分别为92%、92%和89%。

关键数值与推荐

  • S-1推荐剂量为35 mg/m2每日两次(I期确定)。
  • II期客观缓解率40.7%(95%CI 28%-55%),中位无进展生存7.6个月(95%CI 5.6-11.0),中位总生存11.4个月(95%CI 8.1-16.3)。
  • III/IV级中性粒细胞减少发生率40.7%。

临床怎么用

  • 双周SLOG方案可作为转移性胰腺癌的可行治疗选择,需注意中性粒细胞减少的监测。
  • 该方案与改良FOLFIRINOX对比的随机研究正在进行中(NCT03443492)。

局限性

  • 本研究为I/II期单臂试验,样本量有限,疗效需随机对照研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This phase I/II study evaluated the feasibility and efficacy of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG), a triplet regimen, for treating patients with metastatic pancreatic ductal adenocarcinoma (PDAC). METHODS: Patients with chemo-naive, metastatic PDAC were eligible to receive fixed-rate infusion (10 mg/m2/min) of gemcitabine of 800 mg/m2 followed by oxaliplatin of 85 mg/m2 on day 1 plus oral S-1 and leucovorin (20 mg/m2) twice daily from days 1 to 7 in a 2-week cycle. The dose of S-1 would be escalated from 20, 30, 35 to 40 mg/m2 in a 3 + 3 designed phase I part to determine the maximum tolerated dose (MTD) for phase II study, in which the primary end-point was objective response rate (ORR). The recommended dose of S-1 was from phase I. This trial is registered at ClinicalTrials.gov: NCT01415713. RESULTS: Seventy-three patients were enrolled. In the phase I study (n = 19), the MTD of S-1 was 35 mg/m2 twice daily. Of 54 patients in phase II, the ORR was 40.7% (95% confidence interval [CI], 28%-55%). The median progression-free survival and overall survival were 7.6 (95% CI, 5.6-11.0) and 11.4 (95% CI, 8.1-16.3) months, respectively. The most common grade III/IV adverse event was neutropenia (40.7%). Twenty-four percent of patients had SLOG treatment for more than 1 year. The mean relative dose intensities of gemcitabine, oxaliplatin, and S-1 were 92%, 92% and 89%, respectively. CONCLUSION: Biweekly SLOG is a feasible regimen with promising activity and safety profiles. A randomised study comparing SLOG versus modified folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) in advanced PDAC is ongoing (ClinicalTrials.gov: NCT03443492).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chiang NJ, Tsai KK, Hsiao CF, et al. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Eur J Cancer. 2019. PMID: 31765987. doi:10.1016/j.ejca.2019.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。